Jillian K. Cooper
Johns Hopkins University School of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jillian K. Cooper.
Nature Medicine | 1999
Akira Sawa; Gordon W. Wiegand; Jillian K. Cooper; Russell L. Margolis; Alan H. Sharp; Joseph F. Lawler; J. Timothy Greenamyre; Solomon H. Snyder; Christopher A. Ross
Huntington disease (HD) is a genetically dominant condition caused by expanded CAG repeats coding for glutamine in the HD gene product huntingtin. Although HD symptoms reflect preferential neuronal death in specific brain regions, huntingtin is expressed in almost all tissues, so abnormalities outside the brain might be expected. Although involvement of nuclei and mitochondria in HD pathophysiology has been suggested, specific intracellular defects that might elicit cell death have been unclear. Mitochondria dysfunction is reported in HD brains; mitochondria are organelles that regulates apoptotic cell death. We now report that lymphoblasts derived from HD patients showed increased stress-induced apoptotic cell death associated with caspase-3 activation. When subjected to stress, HD lymphoblasts also manifested a considerable increase in mitochondrial depolarization correlated with increased glutamine repeats.
Molecular and Cellular Neuroscience | 1999
Matthew F. Peters; Frederick C. Nucifora; Jonathan Kushi; Holly C. Seaman; Jillian K. Cooper; William J. Herring; Valina L. Dawson; Ted M. Dawson; Christopher A. Ross
Huntingtons disease is a neurodegenerative disorder resulting from expansion of the polyglutamine region in huntingtin. Although huntingtin is normally cytoplasmic, in affected brain regions proteolytic fragments of mutant huntingtin containing the polyglutamine repeat form intranuclear inclusions. Here, we examine the contribution of nuclear localization to toxicity by transiently transfecting neuro-2a cells with an N-terminal huntingtin fragment similar in size to that believed to be present in patients. The huntingtin fragment, HD-N63, was targeted either to the cytoplasm with a nuclear export signal (NES) or to the nucleus with a nuclear localization signal (NLS). The NES decreased the number of cells with aggregates in the nucleus while an NLS had the opposite effect. By cotransfecting HD-N63 with GFP as a marker, we observed direct cell loss with constructs containing expanded polyglutamine repeats. Compared to unmodified HD-N63-75Q, adding an NES reduced cell loss by 57% while an NLS increased cell loss by 111%. These results indicate that nuclear localization of mutant huntingtin fragments plays an important role in cell toxicity.
Neuron | 1999
Gabriele Schilling; Jonathan D. Wood; Kui Duan; Hilda H. Slunt; Vicky Gonzales; Mitsunori Yamada; Jillian K. Cooper; Russell L. Margolis; Nancy A. Jenkins; Neal G. Copeland; Hitoshi Takahashi; Shoji Tsuji; Donald L. Price; David R. Borchelt; Christopher A. Ross
Dentatorubral and pallidoluysian atrophy (DRPLA) is a member of a family of progressive neurodegenerative diseases caused by polyglutamine repeat expansion. Transgenic mice expressing full-length human atrophin-1 with 65 consecutive glutamines exhibit ataxia, tremors, abnormal movements, seizures, and premature death. These mice accumulate atrophin-1 immunoreactivity and inclusion bodies in the nuclei of multiple populations of neurons. Subcellular fractionation revealed 120 kDa nuclear fragments of mutant atrophin-1, whose abundance increased with age and phenotypic severity. Brains of DRPLA patients contained apparently identical 120 kDa nuclear fragments. By contrast, mice overexpressing atrophin-1 with 26 glutamines were phenotypically normal and did not accumulate the 120 kDa fragments. We conclude that the evolution of neuropathology in DRPLA involves proteolytic processing of mutant atrophin-1 and nuclear accumulation of truncated fragments.
Neuroreport | 2003
Shuichi Igarashi; Hokuto Morita; Kyla M. Bennett; Yuji Tanaka; Simone Engelender; Matthew F. Peters; Jillian K. Cooper; Jonathan D. Wood; Akira Sawa; Christopher A. Ross
Huntingtons disease (HD) is an autosomal dominant neurodegenerative disorder caused by the abnormal expansion of a polyglutamine tract in the huntingtin protein. We have developed PC12 cell lines in which the expression of an N-terminal truncation of huntingtin (N63) with either wild type (23Q) or expanded polyglutamine (148Q) can be induced by the removal of doxycycline. Differentiated PC12 cells induced to express N63-148Q showed cellular toxicity reaching up to 50% at 6 days post-induction. Histone acetyltransferase (HAT) activity and global histone acetylation was significantly decreased in cells expressing truncated huntingtin with mutant but not normal huntingtin. These data suggest that altered chromatin modification via reduction in coactivator activity may cause neuronal transcriptional dysregulation and contribute to cellular toxicity.
Journal of Neuropathology and Experimental Neurology | 2007
Gabriele Schilling; Alexandra Klevytska; Andrew T. N. Tebbenkamp; Katrin Juenemann; Jillian K. Cooper; Hilda H. Slunt; Michelle Poirer; Christopher A. Ross; David R. Borchelt
Huntington disease (HD) is caused by the expansion of a glutamine (Q) repeat near the N terminus of huntingtin (htt), resulting in altered conformation of the mutant protein to produce, most prominently in brain neurons, nuclear and cytoplasmic inclusion pathology. The inclusions and associated diffuse accumulation of mutant htt in nuclei are composed of N-terminal fragments of mutant protein. Here, we used a panel of peptide antibodies to characterize the htt protein pathologies in brain tissues from human HD, and a transgenic mouse model created by expressing the first 171 amino acids of human htt with 82Q (htt-N171-82Q). In tissues from both sources, htt pathologic features in nuclei were detected by antibodies to htt peptides 1-17 and 81-90 but not 115-129 (wild-type huntingtin numbering with 23 repeats). Human HEK 293 cells transfected with expression vectors that encode either the N-terminal 233 amino acids of human htt (htt-N233-82Q) or htt-N171-18Q accumulated smaller N-terminal fragments with antibody-binding characteristics identical to those of pathologic peptides. We conclude that the mutant htt peptides that accumulate in pathologic structures of human HD and httN171-82Q in mice are produced by similar, yet to be defined, proteolytic events in a region of the protein near or within amino acids 90-115.
Neurobiology of Disease | 2002
Banghua Sun; Wei Fan; Aldona M. Balciunas; Jillian K. Cooper; Gal Bitan; Shirley Steavenson; Paul Denis; Yunjen Young; Beverly S. Adler; Larry Daugherty; Raffi Manoukian; Gary Elliott; Wenyan Shen; Jane Talvenheimo; David B. Teplow; Mitsuru Haniu; Raj Haldankar; Christopher A. Ross; Martin Citron; William G. Richards
Amino-terminal fragments of huntingtin, which contain the expanded polyglutamine repeat, have been proposed to contribute to the pathology of Huntingtons disease (HD). Data supporting this claim have been generated from patients with HD in which truncated amino-terminal fragments forming intranuclear inclusions have been observed, and from animal and cell-based models of HD where it has been demonstrated that truncated polyglutamine-containing fragments of htt are more toxic than full-length huntingtin. We report here the identification of a region within huntingtin, spanning from amino acids 63 to 111, that is cleaved in cultured cells to generate a fragment of similar size to those observed in patients with HD. Importantly, proteolytic cleavage within this region appears dependent upon the length of the polyglutamine repeat within huntingtin, with pathological polyglutamine repeat-containing huntingtin being more efficiently cleaved than huntingtin containing polyglutamine repeats of nonpathological size.
Science | 2001
Frederick C. Nucifora; Masayuki Sasaki; Matthew F. Peters; Hui Huang; Jillian K. Cooper; Mitsunori Yamada; Hitoshi Takahashi; Shoji Tsuji; Juan C. Troncoso; Valina L. Dawson; Ted M. Dawson; Christopher A. Ross
Human Molecular Genetics | 1999
Gabriele Schilling; Mark W. Becher; Alan H. Sharp; H.A. Jinnah; Kui Duan; Joyce A. Kotzuk; Hilda H. Slunt; Tamara Ratovitski; Jillian K. Cooper; Nancy A. Jenkins; Neal G. Copeland; Donald L. Price; Christopher A. Ross; David R. Borchelt
The Journal of Neuroscience | 2000
Dorotea Rigamonti; Johannes H. Bauer; Claudio De-Fraja; Luciano Conti; Simonetta Sipione; Clara Sciorati; Emilio Clementi; Abigail S. Hackam; Michael R. Hayden; Yong Li; Jillian K. Cooper; Christopher A. Ross; Stefano Govoni; Claudius Vincenz
Human Molecular Genetics | 1998
Jillian K. Cooper; Gabriele Schilling; Matthew F. Peters; William J. Herring; Alan H. Sharp; Zachary Kaminsky; Jamie Masone; Farhat A. Khan; Michael Delanoy; David R. Borchelt; Valina L. Dawson; Ted M. Dawson; Christopher A. Ross